Free Trial
NASDAQ:SRZN

Surrozen Q1 2025 Earnings Report

Surrozen logo
$11.68 +0.28 (+2.46%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$11.56 -0.12 (-1.03%)
As of 08/28/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Surrozen EPS Results

Actual EPS
-$3.13
Consensus EPS
-$1.09
Beat/Miss
Missed by -$2.04
One Year Ago EPS
N/A

Surrozen Revenue Results

Actual Revenue
$0.98 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Surrozen Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Friday, May 9, 2025
Conference Call Time
12:30PM ET

Upcoming Earnings

Surrozen's Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Tuesday, November 4, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Surrozen Earnings Headlines

Surrozen to Present at Upcoming Healthcare Investor Conference
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist Ben Stein—drawing on insights from his own experience and his father’s time advising two U.S. presidents—just released a new report on how to help protect your retirement from the next major crisis.tc pixel
Surrozen Reports Q2 Profit on Gains
See More Surrozen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email.

About Surrozen

Surrozen (NASDAQ:SRZN), a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

View Surrozen Profile

More Earnings Resources from MarketBeat